Loading...

Table of Content

    08 April 2019, Volume 46 Issue 4 Previous Issue    Next Issue
    For Selected: Toggle Thumbnails
    Effect of plasma membrane-associated sialidase NEU3 activity on the proliferation and apoptosis of osteosarcoma MG-63 cells
    Yang Xiao1, Li Si2, Peng Jin3, Wang Lin4, Wu Yilun4, Feng Ying2
    2019, 46 (4):  193-198.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.001
    Abstract ( 463 )   PDF (2142KB) ( 621 )   Save
    Objective To investigate the effect of plasma membrane-associated sialidase 3 (NEU3) activity on the proliferation and apoptosis of osteosarcoma MG-63 cells in vitro. Methods  MG-63 cells were cultured in vitro. Anti-NEU3 antibody (Ab) immunofluorescent staining was used to indicate the cellular localization of NEU3 in MG-63 cells. The cells treated with 0 nmol/L 2-deoxy-2,3didehydro-N-acetyl neuraminic acid (DANA) or 0 μg/ml anti-NEU3 Ab were used as blank control groups. The cells were treated with 10, 20, 50 nmol/L DANA, or 0.5, 1.0, 2.0 μg/ml antiNEU3 Ab for 24 h or 48 h, respectively. The inhibition rates of the cell proliferation and cell apoptosis rates were measured with CCK-8 and flow cytometry. The expression levels of oncogene-related proteins, Ras protein and Bcl-2 protein, were detected by Western blotting. Results  The immunofluorescence result showed that NEU3 was located in the cytoplasm of MG-63 cell. After treating with 0, 10, 20, 50 nmol/L DANA for 48 h, the inhibition rates of cell proliferation were 0, 15.10%±3.23%, 41.46%±2.31%, 64.68%±4.12%, with significant statistical difference (F=99.90, P<0.001), and the following contrast between each two groups met the statistical significance (all P<0.05). After treating with 0, 0.5, 1.0, 2.0 μg/ml anti-NEU3 Ab for 48 h, the inhibition rates of cell proliferation were 0, 9.34%±1.53%, 19.66%±4.18%, 42.50%±5.68%, and the difference was statistically significant (F=25.67, P<0.001), and the following contrast between each two groups met the statistical significance (P<0.05), except the difference between 0.5 and 1.0 μg/ml groups (P>0.05). When the MG-63 cells were treated with 0, 10, 20, 50 nmol/L DANA for 24 h, the cell apoptosis rates were 4.05%±0.07%, 4.15%±0.23%, 12.85%±1.48%, 8.29%±0.86%, respectively, and the difference was statistically significant (F=23.21, P<0.001). And the following contrast between each two groups met the statistical significance (P<0.05), except the differences between 0 nmol/L and 10 nmol/L, 20 nmol/L and 50 nmol/L groups (P>0.05). When the MG-63 cells were treated with 0, 0.5, 1.0, 2.0 μg/ml anti-NEU3 Ab for 24 h, the cell apoptosis rates were 4.05%±0.07%, 20.13%±2.97%, 20.29%±2.82%, 20.58%±0.70%, with statistical significant difference (F=15.36, P=0.001). And the following contrast between each two groups showed that the differences between 0 μg/ml and each treated group were statistically significant (P<0.05), while the differences between two treated groups were not statistically significant (P>0.05). Western blotting results showed that the expression levels of Ras and Bcl-2 decreased with the increasing concentrations of DANA and anti-NEU3. Conclusion  Inhibition of NEU3 enzyme activity can suppress the survival rate of MG63 cells and increase the cell apoptosis. The possible mechanism may be related to the declined expression of oncogene-related proteins Ras and Bcl-2, which suggests that NEU3 may be a possible target for treating osteosarcoma.
    References | Related Articles | Metrics
    Expression and clinic significance of long non-coding RNA ZEB1-AS1 in breast cancer
    Wang Nina, Li Xiaohua, Chen Minli, Zhu Yong
    2019, 46 (4):  199-204.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.002
    Abstract ( 637 )   PDF (2147KB) ( 431 )   Save
    Objective  To detect the expression and clinic significance of long non-coding RNA ZEB1-AS1 in breast cancer. Methods   A total of 130 patients with breast cancer in Baoji Central Hospital of Shaanxi Province from June 2007 to April 2015 were selected. Quantitative real-time PCR (qRT-PCR) was used to detect the expression level of ZEB1-AS1 in breast cancer tissues and corresponding normal tissues, and the relationships between the expression level of ZEB1-AS1 and the clinic characteristics of the patients and their overall survival time were analyzed. siRNA was used to disturb the expression of ZEB1-AS1. CCK-8 assay, clone formation assay and Transwell assay were used to detect the proliferation, cloning ability and migration of breast cancer MCF-7 cells in control group, siRNA-1 group and siRNA-2 group. Results  The expression level of ZEB1-AS1 in breast cancer tissues was higher than that in corresponding normal tissues [M(QR): 0.001 6 (0.005 1) vs. 0.000 9 (0.001 5); Z=-4.426, P<0.001]. The higher expression of ZEB1-AS1 was correlated with lymphatic metastasis (χ2=9.148, P=0.027), negative human epidermal growth factor receptor 2 (χ2=5.039, P=0.025), triple negative breast cancer (χ2=4.597, P=0.032). The patients with the higher expression of ZEB1-AS1 had a shorter overall survival time compared with the patients with the lower expression of ZEB1-AS1 (χ2=14.340, P<0.001). CCK-8 assay showed that knock down of ZEB1-AS1 after 72 h, the absorbance values of the control group, siRNA-1 group and siRNA-2 group were 0.605±0.049, 0.488±0.054, 0.417±0.038 respectively, with a statistically significant different (F=15.936, P<0.001), and the two siRNA groups were significantly inhibited in cell proliferation compared with the control group (both P<0.05). The colonies of the control group, siRNA-1 group and siRNA-2 group were 297.5±11.4, 192.0±12.1, 204.8±12.8 respectively, with a statistically significant different (F=112.526, P<0.001), and the two siRNA groups were significantly inhibited in the cell clone compared with the control group (both P<0.001). The migratory cells numbers of the control group, siRNA-1 group and siRNA-2 group were 184.5±8.6, 147.5±18.6, 57.6±7.3 respectively, with a statistically significant different (F=12.409, P=0.001), and the two siRNA groups were significantly inhibited in the cell migration (both P<0.001). Conclusion  ZEB1-AS1 is overexpressed in breast cancer, overexpression of ZEB1-AS1 induces a shorter overall survival in breast cancer patients, and knock down of ZEB1-AS1 can inhibit the proliferation, migration and colony formation ability of the breast cancer cell line.
    References | Related Articles | Metrics
    Expression of Nestin and its relationship with tamoxifen curative effect and prognosis of patients with breast cancer
    Li Yinmou, Li Jing, Peng Shijun
    2019, 46 (4):  205-210.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.003
    Abstract ( 560 )   PDF (1238KB) ( 467 )   Save
    Objective  To investigate the expression of Nestin and its relationship with tamoxifen curative effect and prognosis of patients with breast cancer. Methods  A total of 82 patients with breast cancer who received tamoxifen therapy after radical mastectomy in Department of Breast Surgery of Enshi Tujia Miao Autonomous Prefecture Central Hospital of Hubei Province from March 2009 to March 2013 were collected. And the paired cancer tissues and adjacent normal tissues preserved in liquid nitrogen were also collected. Fluorescent quantitative real-time PCR (RT-PCR) and immunohistochemistry were used to detect the content of Nestin mRNA and the expression of Nestin in breast cancer tissues. The expression of Nestin in breast cancer tissues and its relationship with clinicopathologic features were analyzed. Breast cancer cell line MCF-7 was selected, small interfering RNA (siRNA) was used to silence Nestin in MCF-7 cells, and the influence on tamoxifen sensitivity was observed. The relationship of Nestin and epithelial-mesenchymal transition (EMT) was detected using Western blotting. Results  The results of RT-PCR indicated that the mRNA level of Nestin in breast cancer tissues was 3.87 times as high as that in paracancerous tissues (6.34±1.56 vs. 1.64±0.52, t=26.140, P<0.001). Immunohistochemical staining suggested that the positive rate of Nestin in breast cancer tissues was 75.61% (62/82), which was significantly higher than that in paracancerous tissues [24.39% (20/82)], with a significant difference (χ2=43.024, P<0.001). The expression of Nestin was related to lymphatic vessel infiltration (χ2=7.499, P=0.006) and lymph node metastasis (χ2=6.770, P=0.034), and it was not related to the age of patients (χ2=3.242, P=0.072), tumor size (χ2=2.358, P=0.308), histological grade (χ2=0.294, P=0.863), ductal infiltrating status (χ2=0.180, P=0.671) and triple negative breast cancer (χ2=0.142, P=0.706). The analysis of Cox risk ratio model showed that Nestin expression (HR=1.982, P<0.001; HR=1.537, P<0.001), lymphatic vessel invasion (HR=2.502, P<0.001; HR=1.715, P<0.001) and lymph node metastasis (HR=1.818, P<0.001; HR=1.446, P<0.001) were independent prognostic risk factors for progress-free survival and overall survival in breast cancer patients. After Nestin knockout in breast cancer cell line MCF-7, the IC50 value of MCF-7 to tamoxifen decreased from (48.05±2.22) μmol/L to (35.59±2.92) μmol/L, with a significant difference (t=6.489, P=0.003). Silencing Nestin significantly up-regulated E-cadherin (7.21±1.15 vs. 1.02±0.01, t=6.654, P=0.024) and down-regulated the mesenchyme index Vimentin (0.17±0.08 vs. 1.01±0.02, t=25.015, P<0.001) in MCF-7 cells. Conclusion  Nestin is over-expressed in breast cancer, which is associated with reduced efficacy of tamoxifen. Nestin may be a new potential prognostic biomarker for breast cancer.
    References | Related Articles | Metrics
    Level and clinical significance of NLR, PLR and CEA in peripheral blood of patients with lung adenocarcinoma
    Wang Min, Fang Haohui
    2019, 46 (4):  211-215.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.004
    Abstract ( 1156 )   PDF (877KB) ( 522 )   Save
    Objective  To investigate the difference of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and carcinoembryonic antigen (CEA) in peripheral blood of patients between lung adenocarcinoma and benign lung disease and their diagnostic values in lung adenocarcinoma. Methods  A total of 91 patients with lung adenocarcinoma admitted to Anhui Chest Hospital from January 2015 to September 2018 were collected as lung adenocarcinoma group and 105 patients with benign lung diseases as control group. The levels of NLR, PLR and CEA in peripheral blood of patients were measured by automatic blood analyzer and immunofluorescence quantitative method. The receiver operating characteristic (ROC) curve and area under curve (AUC) were used to analyze the diagnostic value of the above indicators for lung adenocarcinoma. Results  The NLR and PLR of 91 patients with lung adenocarcinoma were 4.94±0.34 and 306.99±12.56 respectively, which were significantly higher than those of the control group [2.80±0.13 (t=5.882, P<0.001) and 161.98±5.07 (t=10.710, P<0.001)]. The concentration of CEA in lung adenocarcinoma group was (32.71±5.41) ng/ml, which was higher than that in the control group [(3.21±0.21) ng/ml, t=5.453, P<0.001]. NLR was 5.74±0.49 in patients with stage ⅢⅣ, significantly higher than 3.59±0.26 in patients with stage Ⅰ-Ⅱ (t=-3.904, P<0.001). PLR was 347.59±14.33 in patients with stage Ⅲ-Ⅳ, higher than 238.94±18.53 in patients with stage Ⅰ-Ⅱ (t=-4.639, P<0.001). The concentration of CEA was (43.18±8.09) ng/ml in patients with stage Ⅲ-Ⅳ, significantly higher than (15.14±3.49) ng/ml in patients with stage Ⅰ-Ⅱ (t=-3.181, P=0.002). The ROC curve analysis showed that the sensitivity, specificity and accuracy of NLR in the diagnosis of lung adenocarcinoma were 72.50%, 65.70%, 71.42% when 3.05 was the value of cut-off, those of PLR were 83.50%, 81.00%, 83.95% when 202.41 was the cut-off, those of CEA were 85.20%, 89.50%, 86.42% when cut-off was 5.92 ng/ml, and those of the combined detection were 87.90%, 95.20%, 89.01%. The sensitivity, specificity and accuracy of the four methods were significantly different (χ2=16.161, P<0.001; χ2=5.984, P=0.014; χ2=5.809, P=0.016). The sensitivity of the combination was higher than that of NLR alone (χ2=6.787, P=0.009), the specificity of the combination was higher than that of NLR and PLR alone (χ2=23.408, P<0.001; χ2=5.879, P=0.015), and the accuracy of combined detection was significantly higher than that of single detection (χ2=8.865, P=0.003; χ2=6.665, P=0.010; χ2=4.670, P=0.031). The AUC of CEA was 0.900 (95%CI: 0.849-0.938), which was significantly higher than NLR′s 0.752 (95%CI: 0.686-0.811), and there was no significant difference between CEA′s 0.900 and PLR′s 0.865 (95%CI: 0.809-0.910). The AUC of the combined detection was 0.940 (95%CI: 0.897-0.969), which was significantly higher than that of NLR (Z=5.565, P<0.001), PLR (Z=3.252, P=0.007), and CEA (Z=2.109, P=0.035). Conclusion  The levels of NLR, PLR and CEA in lung adenocarcinoma are significantly increased, and they are related to staging. The combination detection of the three has the better diagnostic efficacy in lung adenocarcinoma, which is worth for further clinical promotion.
    References | Related Articles | Metrics
    Prognostic value of serum P-cadherin level in patients with nonsmall cell lung cancer
    Ma Jun1, Luo Judong2, Jing Wenjiang1, Zhang Shulian1, Wang Juanyi1, Fan Zhigang1
    2019, 46 (4):  216-220.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.005
    Abstract ( 494 )   PDF (1043KB) ( 476 )   Save
    Objective  To investigate the prognostic value of serum P-cadherin (P-cad) level in patients with non-small cell lung cancer (NSCLC). Methods  A total of 80 patients with NSCLC in Hanzhong 3201 Hospital of Shaanxi Province from January 2012 to December 2013 were selected as study subjects. The relationships between serum P-cad level and clinicopathological characteristics were analyzed. The Cox regression analysis was used to analyze the risk factors affecting prognosis of NSCLC patients. The survival curve was drawn by Kaplan-Meier method and the difference test was carried out by log-rank method. Results  There were significant differences in lymph node metastasis (χ2=14.31, P<0.001), vascular invasion (χ2=5.56, P=0.018) among NSCLC patients with different levels of serum P-cad. Multivariate Cox regression analysis showed that lymph node metastasis (HR=0.856, 95%CI: 0.702-0.955,P=0.012), TNM stage (ⅢA HR=1.315, 95%CI: 1.058-1.991, P=0.024; ⅢB HR=1.448, 95%CI: 1.124-2.215, P=0.011; Ⅳ HR=1.569, 95%CI: 1.182-2.441, P<0.001) and high level of serum P-cad (HR=1.815, 95%CI: 1.224-3.562, P<0.001) were risk factors for progression-free survival in NSCLC patients, and lymph node metastasis (HR=0.755, 95%CI: 0.652-0.915, P=0.022), poor differentiation (HR=1.622, 95%CI: 1.112-2.015, P<0.001), TNM stage (ⅢA HR=1.335, 95%CI: 1.064-2.014, P=0.011; ⅢB HR=1.489, 95%CI: 1.129-2.297, P<0.001; Ⅳ HR=1.622, 95%CI: 1.192-2.501, P<0.001) and high level of serum P-cad (HR=1.677, 95%CI: 1.193-2.668, P<0.001) were risk factors for overall survival of NSCLC patients. The results of Kaplan-Meier survival curve showed that the overall survival and progression-free survival of patients with high level of serum P-cad were shorter than those of patients with low level of serum P-cad (χ2=5.18, P=0.015; χ2=5.48, P=0.011). Conclusion  High level of serum P-cad is closely related to poor prognosis in NSCLC patients.
    References | Related Articles | Metrics
    Clinical observation of apatinib combined with docetaxel in treatment of advanced serum alpha-fetoprotein-positive  gastric cancer
    Tang Shimin, Liu Li, Dong Huaqiong
    2019, 46 (4):  221-225.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.006
    Abstract ( 523 )   PDF (1022KB) ( 430 )   Save
    Objective  To observe the efficacy and safety of apatinib combined with docetaxel in the third line and above treatment of advanced serum alpha-fetoprotein-positive gastric cancer (AFPGC). Methods  A total of 41 patients with AFPGC from February 2015 to April 2018 in Suining Central Hospital of Sichuan Province were retrospectively analyzed. The patients were divided into experimental group and control group according to different treatment methods, 15 patients in the experimental group received with apatinib combined with docetaxel, and 26 patients in the control group received chemotherapy alone or optimal nutritional support. The short-term efficacy, long-term efficacy and adverse reactions were evaluated by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, progression-free survival (PFS), overall survival (OS) and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Results  After 2 cycles of treatment, no complete remission (CR) was achieved in either group, 4 partial remission (PR), 7 stable disease (SD), 4 progressive disease (PD) in the experimental group, and 2 PR, 7 SD, 17 PD in the control group. The objective response rate (ORR) was 26.67% (4/15) and 7.69% (2/26) respectively in the experimental group and the control group, with no significant difference (χ2=1.433, P=0.231). The disease control rate (DCR) was 73.33% (11/15) and 34.62% (9/26) respectively in the two groups, with significant difference (χ2=5.707, P=0.017). The median PFS of the experimental group and the control group were both 3.0 months, and there was no significant difference between the two groups (χ2=4.425, P=0.350). The median OS were 6.0 months and 4.0 months respectively, and the difference was statistically significant (χ2=5.727, P=0.017). The occurrence rates of leukopenia of the experimental group and the control group were 73.33% (11/15) and 30.77% (8/26), the occurrence rates of hypertension were 40.00% (6/15) and 0 (0/26), the occurrence rates of proteinuria were 26.67% (4/15) and 0 (0/26), the occurrence rates of poor appetite were 80.00% (12/15) and 38.46% (10/26), and the occurrence rates of hemorrhage were 33.33% (5/15) and 3.85% (1/26). The occurrence rates of the above adverse reactions in the experimental group were significantly higher than those in the control group (χ2=6.930, P=0.008; χ2=9.191, P=0.002;  χ2=4.953, P=0.026; χ2=6.600, P=0.010; χ2=4.471, P=0.034), and the differences were statistically significant. There was no significant difference in the incidence of thrombocytopenia, anemia, nausea and vomiting, diarrhea, fatigue and hand-foot syndrome between the two groups (all P>0.05). Conclusion  The DCR of apatinib combined with docetaxel in the third-line and above treatment of advanced AFPGC patients is higher. This scheme can prolong survival period, and the adverse reactions are more serious, but they are basically tolerable.
    Related Articles | Metrics
    Curative effect of TACE combined with Antike in the treatment of primary liver cancer
    Liu Xiaocheng1, Li Chuangui1, Li Weitian2
    2019, 46 (4):  226-230.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.007
    Abstract ( 624 )   PDF (1514KB) ( 512 )   Save
    Objective  To evaluate the curative effect of transcatheter arterial chemoembolization (TACE) combined with Antike in the treatment of primary liver cancer. Methods  The data of 72 patients with primary liver cancer (90 lesions in total) admitted to the First Affiliated Hospital of Hebei North University from August 2016 to December 2017 were retrospectively analyzed. All patients were divided into the observation group (n=36) and the control group (n=36) according to the therapeutic schedule. The patients in the control group (40 foci) were treated with TACE only, and the patients in the observation group (50 foci) received TCAE treatment, oral Antike capsules were taken at the same time with the frequency of three times a day, two capsules each time, and six weeks were planned for one treatment cycle. A total of four cycles were completed. All patients underwent CT enhancement scans one week before TACE treatment and six months after treatment. According to Response Evaluation Criteria in Solid Tumors, complete remission and partial remission were deemed as effectivity.The imaging data of the change of tumor size, postoperative tumor residual, tumor capsule growth and new intrahepatic metastases were analyzed and used to evaluate the curative effect of patients in the two groups. Results   After 6 months of treatment, there were 39 effective lesions in the observation group and 23 in the control group. The total effective rate of the observation group was higher than that of the control group (78.0% vs. 57.5%), and the difference was statistically significant (χ2=4.357, P=0.037). Twenty-three neoplastic capsule lesions were detected in the observation group and 9 in the control group. The detection rate of neoplastic capsule was higher in the observation group than that in the control group (46.0% vs. 22.5%), and the difference was statistically significant (χ2=5.356, P=0.021). There were 27 residual tumors and 5 new intrahepatic metastases in the observation group, 30 residual tumors and 13 new intrahepatic metastases in the control group. The residual tumor rate and neohepatic metastasis rate in the observation group were lower than those in the control group (54.0% vs. 75.0%; 13.9% vs. 36.1%), and the differences were statistically significant (χ2=4.220, P=0.040; χ2=4.741, P=0.029). Conclusion  TACE combined with Antike is safe and effective in the treatment of primary liver cancer. It can improve the total clinical efficiency, promote the growth of tumor capsule, and reduce the recurrence rate and metastasis rate of tumor. It is worthy of clinical application.
    References | Related Articles | Metrics
    Regulating effect of microRNAs in lung cancer stem cells
    Zhao Guoli1,2, Liu Hengyao1, Zhang Yueying2
    2019, 46 (4):  231-234.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.008
    Abstract ( 435 )   PDF (807KB) ( 525 )   Save
    Lung cancer stem cells play an important role in chemoresistance and invasion and metastasis of lung cancer. Increasing evidence sustains that microRNAs (miRNAs) play a major role in regulating tumor angiogenesis, drug resistance and metastasis. Cancer stem cells are considered to be one of the reasons leading to cancer recurrence, metastasis and resistance to chemotherapy, therefore better understanding how miRNAs regulate gene expression in lung cancer stem cells will help identify cancer biomarkers and new therapeutic targets, and will help to develop better treatment strategies for lung cancer.
    References | Related Articles | Metrics
    Effect of histone deacetylase and its inhibitor on tumor
    Liang Jing1,3, Han Sha2, Yao Jing3, Kong Qingsheng2
    2019, 46 (4):  235-238.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.009
    Abstract ( 609 )   PDF (809KB) ( 490 )   Save
    The occurrence and progress of tumor is the result of the interaction of heredity and epigenetics. Histone deacetylation modification, as an important epigenetic modification, plays an important role in tumorigenesis and development. The abnormal expression of histone deacetylase in normal tissues and cells promotes the development of tumor and is related to the proliferation and apoptosis, angiogenesis, metastasis and drug resistance of tumor cells, and becomes a new target of tumor therapy. Histone deacetylase inhibitors as antitumor drugs have a good prospect of application.
    References | Related Articles | Metrics
    Expression and role of Hippo signaling pathway in non-small cell lung cancer
    Wang Zhao, Wang Yingnan, Ni Jixiang, Zhu Jing
    2019, 46 (4):  239-242.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.010
    Abstract ( 549 )   PDF (810KB) ( 604 )   Save
    Hippo signaling pathway plays an important role in the growth and regeneration of animal organs. Studies have shown that the misexpression of Hippo signaling pathway composed of yes-associated protein and trascriptional co-activator with PDZ-binding motif is involved in the development of non-small cell lung cancer (NSCLC) and has synergistic effect with mutant p53. In addition, its overexpression leads to drug resistance in lung cancer treatment and inhibition of its expression may benefit cancer patients. The expression and role of Hippo signaling pathway in NSCLC are described in detail, which is expected to provide a new direction for targeted therapy of lung cancer.
    References | Related Articles | Metrics
    Surgical strategy of non-small cell lung cancer with Ⅲa staging
    Zhao Qingchun, Zhang Zihe, Chen Jun
    2019, 46 (4):  243-247.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.011
    Abstract ( 486 )   PDF (878KB) ( 715 )   Save
    Patients with Ⅲa staging have a large proportion in non-small cell lung cancer (NSCLC). These patients often lost the opportunity to complete excision of the tumor because the tumor have invaded adjacent vital organs when diagnosed. Besides, Ⅲa staging contains a lot of complicated clinical TNM stages, so, the opinions of experts at home and abroad are various about treatment of NSCLC with Ⅲa staging. Neoadjuvant therapy, surgery, radiation therapy and chemotherapy play important roles under different conditions. Especially surgery is occupying a pivotal position in comprehensive therapy of Ⅲa NSCLC.
    References | Related Articles | Metrics
    Progress and value of radiotherapy for non-small cell lung cancer
    Gao Zhao, Yan Wenxing, Liu Linlin
    2019, 46 (4):  248-252.  doi: 10.3760/cma.j.issn.1673-422X.2019.04.012
    Abstract ( 505 )   PDF (881KB) ( 506 )   Save
    With the innovation of radiotherapy equipment and the promotion of targeted therapy and immunotherapy, the therapeutic mode and status of radiotherapy in non-small cell lung cancer (NSCLC) are constantly changing. For early NSCLC, stereotactic radiotherapy may be an alternative to surgery, but the optimal segmentation model still needs to be explored. As for locally advanced NSCLC, postoperative radiotherapy is still controversial for operable patients, the results of consolidated immunotherapy after concurrent chemoradiotherapy in inoperable patients are encouraging, prophylactic cranial irradiation does not improve survival. Local radiotherapy for patients with oligometastasis is expected to prolong survival.
    References | Related Articles | Metrics